Palivizumab (Synagis) for prevention of respiratory illness in children.
Respiratory syncytial virus commonly causes infections that are of little consequence to most of us. However, for the newborn and at-risk older children, infection can mean serious, even life-threatening respiratory illness affecting pulmonary development and resulting in chronic chest disease. Palivizumab is a new medicine of the high-tech era designed specifically to prevent such problems. Its managed entry into clinical practice sets a challenge for health authorities across the country in ensuring most cost-effective delivery of health care.
MacConnachie
A M
AM
D000367:Age Factors; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D002675:Child, Preschool; D003422:Critical Care / Q000379:methods; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D000069455:Palivizumab; D010371:Pediatric Nursing / Q000379:methods; D018357:Respiratory Syncytial Virus Infections / Q000451:nursing / Q000517:prevention & control* / Q000821:virology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab